2. Falcon-Neyra L., Palladino C., Navarro Gomez M.L. et al. Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. Medicine (Baltimore). 2016; 95(24): e3842. https://www.ncbi.nlm.nih.gov/pubmed/27310962.

3. Mollan K.R., Smurzynski M., Eron J.J., Daar E.S., Campbell T.B., Sax P.E., Gulick R.M., Na L., O’Keefe L., Robertson K.R., Tierney C. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann. Intern. Med. 2014; 161(1): 1–10. DOI: 10.7326/M14-0293

4. Sheng-Li Li, Peng Xu, Lei Zhang, Gui-Xiang Sun, Zhao-Jun Lu. Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis. HIV Clin. Trials. 2014; 15(6): 261–8. DOI: 10.1310/hct1506–261.

5. Bangsberg D.R., Ragland K., Monk A., Deeks S.G. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24(18): 2835–40.

6. Sax P.E., Meyers J.L., Mugavero M., Davis K.L. Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States. PLoS One 2012; 7(2): e31591. DOI: 10.1371/journal.pone.0031591.

7. Sutton S.S., Hardin J.W., Bramley T.J., D’Souza A.O., Bennett C.L. Single-versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am. J. Manag. Care 2016; 22(4): 242–8.

8. Sutton S.S., Magagnoli J., Hardin J.W. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy. Pharmacotherapy 2017; 37(2): 204–13. DOI: 10.1002/phar.1889.

9. EACS Guidelines, 9.0, 2017. European AIDS Clinical Society. https://eacs-editors.sanfordguide.com/

10. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach - Second edition. June 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/11

11. Airoldi M., Zaccarelli M., Bisi L., Bini T., Antinori A., Mussini C., Bai F., Orofino G., Sighinolfi L., Gori A., Suter F., Maggiolo F. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer. Adherence 2010; 13: 115–25. https://doi.org/10.2147/PPA.S10330

12. Antinori A., Angeletti C., Ammassari A., Sangiorgi D., Giannetti A., Buda S., Girardi E., Esposti L.D. Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study. J. Int. AIDS Soc. 2012; 15(Suppl 4): 18098. DOI: 10.7448/ias.15.6.18098.

13. Molina J.M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., Supparatpinyo K., Walmsley S., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238–46.

14. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., Wu H., Zorrilla C., Crauwels H., Rimsky L.T., Vanveggel S., Boven K. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229–37.

15. Cohen C., Wohl D., Arribas J.R., Wohl D., Arribas J.R., Henry K., Van Lunzen J., Bloch M., Towner W., Wilkins E., Ebrahimi R., Porter D., White K., Walker I., Chuck S., De-Oertel Sh., Fralich T. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected adults. AIDS 2014; 28: 989–97.

16. Palella F.J., Fisher M., Tebas P., Gazzard B., Ruane P., Van Lunzen J., Shamblaw D., Flamm J., Ebrahimi R., Porter.,

White K., Hindman J., Elbert E., De-Oertel S., Fralich T.. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28: 335–44. DOI: 10.1097/QAD.0000000000000087

17. Lombard J., Bunupuradah T., Flynn P.M., Ramapuram J., Ssali F., Crauwels H., Hoogstoel A., Van Eygen V., Stevens M. Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. Pediatr. Infect. Dis. J. 2016; 35(11): 1215–21.

18. Jantarabenjakul W., Anugulruengkitt S., Kasipong N., Thammajaruk N. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. Antivir. Ther. 2017 (10). DOI: 10.3851/IMP3198.

For citations: Voronin E.E., Latysheva I.B., Mussini C.HIV-infected children are a special patient group. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (3):71–5